title: Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential.
abstract: Mogamulizumab (KW-0761) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets CC chemokine receptor 4 (CCR4). It has shown promising therapeutic potential in phase I and II clinical trials and is currently being investigated for efficacy in treating cutaneous T-cell lymphoma (CTCL). We review the mechanism of action of mogamulizumab and its role in treating CTCL. We also discuss the results of major clinical trials.
authors.affiliation: Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Madeleine
authors.initials: M
authors.lastname: Duvic
authors.affiliation: University of Utah School of Medicine, Salt Lake City, UT, USA.
authors.forename: Mark
authors.initials: M
authors.lastname: Evans
authors.affiliation: Department of Dermatology, The University of Texas MD Anderson Cancer Center, Pickens Tower, FCT11.6097, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
authors.forename: Casey
authors.initials: C
authors.lastname: Wang
keywords: cutaneous T-cell lymphoma; mogamulizumab; peripheral T-cell lymphoma